Výsledky vyhledávání - "MESH: Melarsoprol"

Insights into antitrypanosomal drug mode-of-action from cytology-based profiling

Autor: Thomas, James A., Baker, Nicola, Hutchinson, Sebastian, Dominicus, Caia, Trenaman, Anna, Glover, Lucy, Alsford, Sam, Horn, David

Publikováno v: PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Public Library of Science, 2018, 12 (11), pp.e0006980. ⟨10.1371/journal.pntd.0006980⟩
PLoS Neglected Tropical Diseases, Vol 12, Iss 11, p e0006980 (2018)
PLoS Neglected Tropical Diseases, 2018, 12 (11), pp.e0006980. ⟨10.1371/journal.pntd.0006980⟩

Chemotherapy continues to have a major impact on reducing the burden of disease caused by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal drugs typically remains unclear or only partially characterised. This is the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::31f45f186ae5f4e445bd3a805273919e
https://hal-pasteur.archives-ouvertes.fr/pasteur-03107158

Zobrazit plný text záznamu

Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second‐StageTrypanosoma brucei gambienseSleeping Sickness

Autor: François Xavier N'Siesi, Simon Van Nieuwenhove, Sylvie Bisser, Constantin Miaka Mia Bilenge, Veerle Lejon, Pierre-Marie Preux, Philippe Büscher

Publikováno v: Scopus-Elsevier
Journal of Infectious Diseases
Journal of Infectious Diseases, Oxford University Press (OUP), 2007, 195 (3), pp.322-9. ⟨10.1086/510534⟩

Background. Treatment of second-stage sleeping sickness relies mainly on melarsoprol. Nifurtimox has been successfully used to cure melarsoprol-refractory sleeping sickness caused by Trypanosoma brucei gambiense infection. Methods. An open, randomize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbd3805533ce5a7b8454f9cd2983e3a
https://doi.org/10.1086/510534

Zobrazit plný text záznamu

Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs

Publikováno v: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2014, 69 (3), pp.651-663. ⟨10.1093/jac/dkt442⟩

Objectives: Trypanosoma brucei drug transporters include the TbAT1/P2 aminopurine transporter and the high-affinity pentamidine transporter (HAPT1), but the genetic identity of HAPT1 is unknown. We recently reported that loss of T. brucei aquaglycero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::61002478b01320a5ea5dac41a2b03c61
https://hal-pasteur.archives-ouvertes.fr/pasteur-03107152/file/dkt442.pdf

Zobrazit plný text záznamu

Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes

Autor: David Horn, Michael P. Barrett, Lucy Glover, Nicola Baker, Harry P. de Koning, David Aguinaga Andrés, Jane C. Munday

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2012, 109 (27), pp.10996-11001. ⟨10.1073/pnas.1202885109⟩

African trypanosomes cause sleeping sickness in humans, a disease that is typically fatal without chemotherapy. Unfortunately, drug resistance is common and melarsoprol-resistant trypanosomes often display cross-resistance to pentamidine. Although me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9ce7c29a0ef3ade746acd2bf72720e
https://hal-pasteur.archives-ouvertes.fr/pasteur-03107134

Zobrazit plný text záznamu

Polysomnography as a diagnosis and post-treatment follow-up tool in human African trypanosomiasis: a case study in an infant

Autor: Bébène Bandzouzi, Ghislain Mpandzou, Alain Buguet, Philippe Vincendeau, Raymond Cespuglio, Stéphane Ngampo, Bernard Bouteille

Publikováno v: Journal of the Neurological Sciences
Journal of the Neurological Sciences, Elsevier, 2011, 305 (1-2), pp.112-5. ⟨10.1016/j.jns.2011.03.002⟩

International audience; Gambian (Trypanosoma brucei gambiense) human African trypanosomiasis (HAT) evolves from the hemolymphatic stage 1, treated with pentamidine, to the meningoencephalitic stage 2, often treated with melarsoprol. This arseniate ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dae214db3083148b8f6e1669d38efb9
https://hal-unilim.archives-ouvertes.fr/hal-00933524

Zobrazit plný text záznamu

Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis

Autor: George Gettinby, Barbara Bradley, Christopher McCabe, Stéphane Gibaud, Michael P. Barrett, Peter G. E. Kennedy, Amy J. Jones, Jean Rodgers

Publikováno v: PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Public Library of Science, 2011, 5 (9), pp.e1308. ⟨10.1371/journal.pntd.0001308⟩
PLoS Neglected Tropical Diseases, Vol 5, Iss 9, p e1308 (2011)

Human African trypanosomiasis (HAT), or sleeping sickness, results from infection with the protozoan parasites Trypanosoma brucei (T.b.) gambiense or T.b.rhodesiense and is invariably fatal if untreated. There are 60 million people at risk from the d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e73ff8b05aafd2d8eb2139be83a36f4
https://hal.archives-ouvertes.fr/hal-00689712

Zobrazit plný text záznamu

Arsthinol nanosuspensions: pharmacokinetics and antileukemic activity on NB4 promyelocytic leukemia cells

Autor: Stéphane Gibaud, Imane Ajana, Alain Astier

Publikováno v: J Pharm Pharmacol
J Pharm Pharmacol, 2009, 61 (10), pp.1295-301. ⟨10.1211/jpp/61.10.0004⟩
Scopus-Elsevier

Objectives The organoarsenical arsthinol was used in the 1950s in the treatment of amoebiasis and yaws and was considered as ‘highly tolerated’. The aim of this work was to study its anti-leukaemic activity and to develop nanosuspensions of the d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c261b1f6456cf7cca8bf5715bc51aef0
https://hal.archives-ouvertes.fr/hal-00689719/document

Zobrazit plný text záznamu

Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice

Autor: Alain Astier, Marc Muchow, Siham Ben Zirar, Stéphane Gibaud

Publikováno v: European Journal of Pharmaceutics and Biopharmaceutics
European Journal of Pharmaceutics and Biopharmaceutics, Elsevier, 2008, 70 (2), pp.649-56. ⟨10.1016/j.ejpb.2008.05.012⟩

International audience; The aim of this work was to develop and compare two formulations of melarsoprol (nanosuspension and hydroxypropyl-beta-cyclodextrin inclusion complex). The arsenic concentrations in the organs have been assessed on a mouse mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b15eb08a73663b3f64c329d27645db7
https://pubmed.ncbi.nlm.nih.gov/18582565

Zobrazit plný text záznamu

Melarsoprol-cyclodextrins inclusion complexes

Autor: Isabelle Fries, Alain Astier, Stéphane Gibaud, Pierre Mutzenhardt, Siham Ben Zirar

Publikováno v: International Journal of Pharmaceutics
International Journal of Pharmaceutics, Elsevier, 2005, 306 (1-2), pp.107-21. ⟨10.1016/j.ijpharm.2005.09.003⟩

International audience; Melarsoprol, a water-insoluble drug, is mainly used in the treatment of trypanosomiasis and has demonstrated an in vitro activity on myeloid and lymphoid leukemia derived cell lines. It is marketed as a very poorly tolerated n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5142edada41fec8f53da91a4bf344c15
https://hal.archives-ouvertes.fr/hal-00399630/document

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání